Aridis Pharmaceuticals Inc. · OTC:ARDS
Aridis Pharmaceuticals — Maxim ID Conference 2020
9 slides from Aridis Pharmaceuticals's conference presentation, May 5, 2020
Slide 1: Novel Anti-infectives Focusing on Lung Infections
Novel Anti-infectives Focusing on Lung Infections Vu Truong Maxim ID Conf. 5May2020 Aridis Pharmaceuticals 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements These forward-looking statements relate to future events or future financial performance of the Company. All such forward-looking statements involve risks and uncertainties and are not guaranties of future performance. An investment in the securities of Aridis is speculati
Slide 3: Non-Antibiotic Anti-infectives Focusing on Lung Infections
Non-Antibiotic Anti-infectives Focusing on Lung Infections Antibiotics: 1 molecular target Broad spectrum 1 molecular target Narrow spectrum: Many molecular targets Broad spectrum: Anti-S. aureus Immunotherapy using monoclonal About 30% of bacteria genes are iron dependent. antibody from convalescen
Slide 4: Lead Phase 3 Clinical Program: AR-301 anti-S. aureus mAb
Lead Phase 3 Clinical Program: AR-301 anti-S. aureus mAb ▪ Anti-S. aureus alphatoxin mAb being clinically evaluated as superiority trial in VAP patients ▪ Fully human mAb discovered from convalescent pneumonia patient ▪ Encouraging Phase 2 data in HAP/VAP patients Ph2 data: Trend toward improvement
Slide 5: Phase 1/2 Clinical Program: AR-501 Inhaled Gallium Citrate
Phase 1/2 Clinical Program: AR-501 Inhaled Gallium Citrate ▪ Mechanism of action: iron analog, subverts multiple key functions in bacteria ▪ Once-per-week inhaled therapy for chronic treatment of bacterial infection in CF ▪ On-going Phase 1/2 supported by CF Foundation [Ph1 data in 1H2020, Ph2 full
Slide 6: SARS-CoV-2 Monoclonal Antibody Discovery & Manufacturing Using APEX Platform Technology
SARS-CoV-2 Monoclonal Antibody Discovery & Manufacturing Using APEXTM Platform Technology Vu Truong Maxim ID Conf. 28Apr2020 Aridis Pharmaceuticals 6
Slide 7: Monoclonal Antibody from Convalescent COVID-19 Patient
Monoclonal Antibody from Convalescent COVID-19 Patient ▪ In a pandemic setting where the protective target/antigen is unknown, mAbs from convalescent COVID-19 patients provide a high probability of clinical success ▪ Neutralization domains on ACE2 receptor are known ▪ Challenges • Not all neutralizi
Slide 8: COVID-19 mAb Discovery Strategies
COVID-19 mAb Discovery Strategies ▪ Target product: mAb cocktail to several key surface assessible proteins for broader coverage ▪ Use wildtype-like SARS-CoV-2 VLP to identify protective epitopes & potential mAbs candidates ▪ Protective, neutralizing epitopes from mouse studies guide the screening o
Slide 9: COVID-19 mAb Development & Manufacturing
COVID-19 mAb Development & Manufacturing ▪ The entire B-cells from COVID-19 patients is screened at single cell level for highly neutralizing mAbs using APEXTM Nanoarrays ▪ APEXTM mAb cell line and production platform technology is leveraged to rapidly manufacture mAbs at ~half the manufacturing cyc